PL2094658T3 - Związki tetrahydrocyklopenta[b]indolowe jako modulatory receptora androgenowego - Google Patents

Związki tetrahydrocyklopenta[b]indolowe jako modulatory receptora androgenowego

Info

Publication number
PL2094658T3
PL2094658T3 PL07844898T PL07844898T PL2094658T3 PL 2094658 T3 PL2094658 T3 PL 2094658T3 PL 07844898 T PL07844898 T PL 07844898T PL 07844898 T PL07844898 T PL 07844898T PL 2094658 T3 PL2094658 T3 PL 2094658T3
Authority
PL
Poland
Prior art keywords
tetrahydrocyclopenta
androgen receptor
receptor modulators
indole compounds
indole
Prior art date
Application number
PL07844898T
Other languages
English (en)
Polish (pl)
Inventor
Konstantinos Gavardinas
Jonathan Edward Green
Prabhakar Kondaji Jadhav
Donald Paul Matthews
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL2094658T3 publication Critical patent/PL2094658T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
PL07844898T 2006-11-20 2007-11-06 Związki tetrahydrocyklopenta[b]indolowe jako modulatory receptora androgenowego PL2094658T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86648406P 2006-11-20 2006-11-20
EP07844898A EP2094658B1 (en) 2006-11-20 2007-11-06 Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
PCT/US2007/083745 WO2008063867A2 (en) 2006-11-20 2007-11-06 Tetrahydrocyclopenta[b] indole compounds as androgen receptor modulators

Publications (1)

Publication Number Publication Date
PL2094658T3 true PL2094658T3 (pl) 2012-05-31

Family

ID=39415431

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07844898T PL2094658T3 (pl) 2006-11-20 2007-11-06 Związki tetrahydrocyklopenta[b]indolowe jako modulatory receptora androgenowego

Country Status (36)

Country Link
US (1) US7968587B2 (Direct)
EP (1) EP2094658B1 (Direct)
JP (1) JP5399259B2 (Direct)
KR (1) KR101121471B1 (Direct)
CN (1) CN101541749B (Direct)
AR (1) AR063559A1 (Direct)
AT (1) ATE538091T1 (Direct)
AU (1) AU2007324046B2 (Direct)
BR (1) BRPI0719092B8 (Direct)
CA (1) CA2670340C (Direct)
CL (1) CL2007003182A1 (Direct)
CO (1) CO6190513A2 (Direct)
CR (1) CR10802A (Direct)
CY (1) CY1112284T1 (Direct)
DK (1) DK2094658T3 (Direct)
EA (1) EA015627B1 (Direct)
EC (1) ECSP099350A (Direct)
ES (1) ES2376048T3 (Direct)
HR (1) HRP20120032T1 (Direct)
IL (1) IL198410A (Direct)
JO (1) JO2800B1 (Direct)
MA (1) MA31072B1 (Direct)
MX (1) MX2009005251A (Direct)
MY (1) MY154547A (Direct)
NO (1) NO342531B1 (Direct)
NZ (1) NZ576296A (Direct)
PE (1) PE20081161A1 (Direct)
PL (1) PL2094658T3 (Direct)
PT (1) PT2094658E (Direct)
RS (1) RS52191B (Direct)
SI (1) SI2094658T1 (Direct)
TN (1) TN2009000189A1 (Direct)
TW (1) TWI398438B (Direct)
UA (1) UA98777C2 (Direct)
WO (1) WO2008063867A2 (Direct)
ZA (1) ZA200903096B (Direct)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
BRPI0907844B8 (pt) 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
ES2396612T3 (es) * 2008-05-16 2013-02-22 Eli Lilly & Company Tetrahidrociclopenta[b]indoles como moduladores del receptor de andrógenos
AR078862A1 (es) 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
JP5964756B2 (ja) 2010-02-04 2016-08-03 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
DK2568806T3 (en) 2010-05-12 2016-08-15 Radius Health Inc therapy Programs
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
EP2621901B1 (en) 2010-09-28 2015-07-29 Radius Health, Inc Selective androgen receptor modulators
BR112013028895A2 (pt) 2011-05-10 2016-08-09 Bayer Ip Gmbh (tio)carbonilamidinas bicíclicas
CN103265479B (zh) * 2013-06-14 2017-12-08 南开大学 一种6‑氯甲基烟酸叔丁酯的合成方法
CA2943611A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
SG11201811225RA (en) 2016-06-22 2019-01-30 Radius Health Inc Ar+ breast cancer treatment methods
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
KR102881465B1 (ko) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
AU2019297421B2 (en) 2018-07-04 2024-08-29 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD 1901-2HCL
CA3128510A1 (en) 2019-02-12 2020-08-20 Radius Pharmaceuticals, Inc. Processes and compounds
JP2023511612A (ja) * 2020-01-27 2023-03-20 エイルゲン ファーマ リミテッド 腎臓疾患の治療のためのテトラヒドロシクロペンタ［ｂ］インドール化合物
US11986461B1 (en) * 2023-08-24 2024-05-21 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
WO2001027086A1 (en) * 1999-10-14 2001-04-19 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline derivatives
US7160909B2 (en) 2001-08-09 2007-01-09 Eli Lilly And Company Cyclopenta[b]indole derivatives as sPLA2 inhibitors
DE10164564B4 (de) 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
WO2003097598A1 (en) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
ES2414604T3 (es) * 2004-03-03 2013-07-22 Eli Lilly And Company Moduladores del receptor nuclear de hormonas esteroides de derivados bicíclicos sustituidos con indol
JP2008520674A (ja) * 2004-11-22 2008-06-19 スミスクライン ビーチャム コーポレーション Ｈｃｖインヒビター
CA2588384A1 (en) 2004-11-23 2006-06-22 Ptc Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
US7297704B2 (en) 2005-02-17 2007-11-20 Wyeth Cycloalkyfused indole, benzothiophene, benzofuran and idene derivatives
CA2612723A1 (en) 2005-06-24 2007-01-04 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
ES2396612T3 (es) 2008-05-16 2013-02-22 Eli Lilly & Company Tetrahidrociclopenta[b]indoles como moduladores del receptor de andrógenos

Also Published As

Publication number Publication date
CR10802A (es) 2009-07-13
NZ576296A (en) 2011-11-25
KR20090082229A (ko) 2009-07-29
EP2094658B1 (en) 2011-12-21
EP2094658A2 (en) 2009-09-02
MA31072B1 (fr) 2010-01-04
TW200827347A (en) 2008-07-01
AU2007324046A1 (en) 2008-05-29
CL2007003182A1 (es) 2008-06-27
EA200970500A1 (ru) 2009-10-30
ECSP099350A (es) 2009-06-30
CA2670340A1 (en) 2008-05-29
MX2009005251A (es) 2009-08-19
ES2376048T3 (es) 2012-03-08
PE20081161A1 (es) 2008-08-15
WO2008063867A3 (en) 2008-07-31
IL198410A0 (en) 2010-02-17
ZA200903096B (en) 2010-07-28
DK2094658T3 (da) 2012-02-13
HRP20120032T1 (hr) 2012-02-29
HK1134089A1 (en) 2010-04-16
US7968587B2 (en) 2011-06-28
CY1112284T1 (el) 2015-12-09
CN101541749A (zh) 2009-09-23
NO20092103L (no) 2009-05-28
US20100069404A1 (en) 2010-03-18
CN101541749B (zh) 2013-03-27
JO2800B1 (en) 2014-03-15
UA98777C2 (en) 2012-06-25
RS52191B (sr) 2012-10-31
BRPI0719092B1 (pt) 2020-08-18
PT2094658E (pt) 2012-02-22
ATE538091T1 (de) 2012-01-15
CO6190513A2 (es) 2010-08-19
TN2009000189A1 (en) 2010-10-18
SI2094658T1 (sl) 2012-04-30
AR063559A1 (es) 2009-02-04
JP2010510231A (ja) 2010-04-02
AU2007324046B2 (en) 2012-04-05
BRPI0719092B8 (pt) 2021-05-25
NO342531B1 (no) 2018-06-11
MY154547A (en) 2015-06-30
EA015627B1 (ru) 2011-10-31
KR101121471B1 (ko) 2012-02-28
BRPI0719092A2 (pt) 2013-12-03
WO2008063867A2 (en) 2008-05-29
IL198410A (en) 2013-09-30
CA2670340C (en) 2014-05-20
TWI398438B (zh) 2013-06-11
JP5399259B2 (ja) 2014-01-29

Similar Documents

Publication Publication Date Title
IL198410A0 (en) Tetrahydrocyclopenta [b] indole compounds as androgen receptor modulators
PL2176220T3 (pl) Pochodne pirolidyn-2-onu jako modulatory receptora androgenowego
PT2297100E (pt) Moduladores dos receptores de andrógenos tetra-hidrociclopenta[b]indoles
IL200922A0 (en) 8-oxy-quinoline derivatives as bradykinin b2 receptor modulators
EP2049520A4 (en) indole compounds
ZA200807551B (en) Selective androgen receptor modulators
GB2456290B (en) Distributed protocol for authorisation
ZA200902585B (en) Indole compound
EP2179061A4 (en) GREAT LIKE RECEPTOR MODULATORS
IL193176A0 (en) Benzoyl-piperidine derivatives as 5ht2/d3 modulators
IL211821A0 (en) The compounds as the estrogen related receptors modulators and the uses thereof
ZA201100539B (en) Oxindole compounds
IL207684A0 (en) Substituted indole derivatives
GB0701992D0 (en) Grehlin Receptor Modulators
ZA201101707B (en) Novel imidazolidine compounds as androgen receptor modulators
ZA201002268B (en) Benzothiazoles as ghrelin receptor modulators
IL211822A0 (en) The compounds as the estrogen related receptors modulators and the uses thereof
ZA200905265B (en) Indole derivatives
ZA200900843B (en) Indole compounds
ZA200806810B (en) Benzoyl-piperidine derivatives as 5HT2/D3 modulators
ZA200806237B (en) Cannibinoid receptor modulators
ZA200907546B (en) New progesterone receptor modulators
PL1991559T3 (pl) Pochodne oksy-steroidowe jako selektywne modulatory receptora progesteronu
HK1160114A (en) Novel imidazolidine compounds as androgen receptor modulators
HK1143376A (en) Benzothiazoles as ghrelin receptor modulators